Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07007195 · ClinicalTrials.gov registry record · Early Phase 1
Smart Olfaction App to Reduce Relapse
A Early Phase 1 study, sponsored by University of Houston.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 132
- Enrollment target
NCT07007195 is a Early Phase 1 study that is actively recruiting participants, run by University of Houston. The registered enrollment target is 132 participants.
The verdict
NCT07007195, a Early Phase 1 study, is actively recruiting participants, sponsored by University of Houston.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 132 participants
- Enrollment target
Study Summary
The proposed project aims to refine and test a novel biobehavioral smoking cessation intervention that integrates the strategic application of olfactory stimulation to reduce cigarette craving with an established smartphone-based smoking cessation application. The specific aims of this study are: (1) refine the design and methodology of our olfactory stimulation delivery system (OSDS) and (2) compare, in a pilot randomized controlled trial (RCT), the effects of a smartphone based app for smoking cessation (Smart-T) with and without the OSDS on smoking cessation outcomes.
Interventions
- DEVICE Ad Libitum Use followed by Instructed Use of the Inspire Device
- DEVICE Instructed Use followed by Ad Libitum Use of the Inspire Device
- DEVICE Smart-T Smoking Cessation App with the Inspire Device Condition
- DEVICE Smart-T Smoking Cessation App Without the Inspire Device Condition
- DRUG Nicotine replacement therapy (NRT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2026-04-22 |
| Est. Completion | 2027-08-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07007195
The ClinicalTrials.gov registry entry for NCT07007195 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 132 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Houston, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Ad Libitum Use followed by Instructed Use of the Inspire Device is the first listed.
NCT07007195 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07007195 about?
NCT07007195 is a clinical study titled "Smart Olfaction App to Reduce Relapse". The proposed project aims to refine and test a novel biobehavioral smoking cessation intervention that integrates the strategic application of olfactory stimulation to reduce cigarette craving with an established smartphone-based smoking cessation application. The specific aims of this study are: (1...
What is the current status of trial NCT07007195?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 132 participants. The study started on 2026-04-22. Estimated completion is 2027-08-31.
What interventions are being tested in trial NCT07007195?
The interventions under investigation include: Ad Libitum Use followed by Instructed Use of the Inspire Device (DEVICE), Instructed Use followed by Ad Libitum Use of the Inspire Device (DEVICE), Smart-T Smoking Cessation App with the Inspire Device Condition (DEVICE), Smart-T Smoking Cessation App Without the Inspire Device Condition (DEVICE), Nicotine replacement therapy (NRT) (DRUG).
Who is sponsoring clinical trial NCT07007195?
This trial is sponsored by University of Houston, which has 64 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.